Background: Carotid angioplasty and stenting is under investigation in clinical trials as an alternative to endarterectomy. Some clinicians have hypothesized that stenting would be applicable for patients at high risk who need carotid revascularization. To further test this hypothesis, we stratified our carotid endarterectomy procedures according to current carotid stent protocols. Methods: We reviewed our computerized registry and the clinical charts of patients who underwent carotid endarterectomy. Each procedure was categorized as high risk or low risk, according to the following six separate high-risk factors: 1, severe cardiac dysfunction; 2, the requirement for combined coronary and carotid vascularization; 3, severe pulmonary dysfunction; 4, contralateral internal carotid artery occlusion; 5, previous ipsilateral carotid endarterectomy; and 6, anatomically limited access for carotid endarterectomy. Rates of stroke at 30 days, cardiac complications, and death were tabulated. Results: Between January 1, 1998, and December 31, 2000, 415 carotid endarterectomies were performed on 389 patients. Ninety-eight procedures (23.6%) were classified as high risk on the basis of the following factors: 1, severe cardiac dysfunction (n = 30); 2, requirement for combined coronary and carotid revascularization (n = 14); 3, severe pulmonary dysfunction (n = 8); 4, contralateral carotid occlusion (n = 31); 5, previous ipsilateral carotid endarterectomy (n = 25); and 6, anatomically limited access (n = 4). Seven patients had ipsilateral postoperative strokes (1.7%), with two additional patients having contralateral hemispheric strokes. One patient died from exacerbation of congestive heart failure 9 days after undergoing a second carotid endarterectomy. The total stroke and death rate was 2.6% for all the patients. Two of the 98 procedures in the high-risk group were complicated with ipsilateral stroke (2.0%) as compared with six of the 317 low-risk procedures (1.9%; P = 1). Six procedures were complicated with cardiac dysfunction after surgery, including myocardial infarction, congestive heart failure, or the new onset of atrial fibrillation. Three cardiac complications occurred in the low-risk group (1%), and three occurred in the high-risk group (3.1%; P = .15). Conclusion: This series shows that patients at high risk can undergo carotid endarterectomy with stroke rates equivalent to the rates of patients at low risk. The cardiac morbidity rate may be increased in the high-risk group. Carotid stenting is unlikely to offer any improvement in stroke risk as compared with carotid endarterectomy, but stenting may reduce non-stroke morbidity rates associated with some high-risk
sive disease of the carotid bifurcation, when the surgical procedure has been used rather effectively. Golledge et al 4 recently reported an analysis of multiple series that identified the inferiority of carotid angioplasty when compared with endarterectomy. In addition, recent multicenter prospective randomized trial results of carotid stenting versus endarterectomy showed a stroke and death rate of 12.1% at 1 year for stenting and a stroke and death rate of 3.6% for CEA. 5 On the basis of a futility analysis, this clinical trial was terminated after 219 of the planned 700 patients were enrolled. 5 Because many studies have shown an inferiority of carotid stenting for routine carotid revascularization, [4] [5] [6] [7] [8] subsequent studies have sought the identification of certain subset patient populations that may be more appropriate for stenting. Occasionally, patients are considered to be at high risk for surgical procedures and are not offered CEA. These patients then undergo treatment with medical therapy, including antiplatelet medication and control of other risk factors, including hypertension, hyperlipidemia, and smoking. Surprisingly, some clinicians have advocated the use of stenting to avoid general anesthesia. However, CEA can be performed with local or regional anesthesia with similarly low stroke rates. 9, 10 Carotid endarterectomy (CEA) has been wellestablished as an effective means for the reduction of stroke for symptomatic and asymptomatic carotid stenosis. 1, 2 With technologic advances, there have been additional innovative approaches to the treatment of carotid artery stenosis. Specifically, percutaneous transluminal angioplasty and stenting has been explored as an alternative for CEA in some patients. Initial report results showed a stroke rate of 9.7%, 3 but because this technique has been modified and improved during the last several years, stroke rates may be reduced. However, the efficacy of this technique remains uncertain, especially for occlu-Carotid stenting protocols have been initiated for the evaluation of a high-risk patient population on the basis of certain physiologic and anatomic risk factors. Ouriel and his colleagues 11 have observed that certain medical risk factors, including coronary, pulmonary, or renal disease, are associated with a higher rate of stroke, death, or myocardial infarction (MI) after CEA. In addition, Rothwell, Slattery, and Warlow 12 examined medical factors and found that female sex, systolic hypertension, and the presence of peripheral vascular disease were associated with a higher risk of stroke and death. They also identified the following anatomic criteria that were associated with a higher risk of stroke and death: contralateral carotid artery occlusion, ipsilateral internal carotid siphon stenosis, or ipsilateral external carotid artery stenosis. Some of these criteria have been implemented in trials that evaluated carotid stenting in patients at high risk. We then sought to evaluate the impact of these factors on stroke risk, morbidity, and mortality rates in a population of patients who underwent CEA.
METHODS
During a 3-year period from January 1, 1998, to December 31, 2000, 415 consecutive CEAs were performed on 389 patients by five different surgeons at the University of Alabama at Birmingham and the Birmingham Veteran's Affairs Medical Center. Consecutive operations were prospectively entered into a computerized registry, which included end points of stroke, death, and MI. In addition, risk factors, including the presence of coronary disease, hypertension, smoking, chronic lung disease, obesity, and diabetes, were tracked prospectively. We then retrospectively applied the following risk factors for the classification of each procedure as high risk or low risk. The high-risk factors included: 1, severe cardiac dysfunction with a left ventricular ejection fraction of less than 30% or a New York Heart Association classification of 3 or 4 angina (severe cardiac dysfunction was also defined as MI in the 4 weeks before surgery or coronary bypass grafting operation in the 6 weeks before surgery); 2, requirement for carotid and coronary or major vascular procedure within 30 days of surgery; 3, severe pulmonary dysfunction, defined as a forced expiratory volume in 1 second of less than 1.0 liters or the requirement for home oxygen; 4, the presence of contralateral carotid occlusion identified with carotid ultrasound scanning or angiography; 5, a previous ipsilateral CEA; and 6, anatomically limited access, including a high cervical internal carotid artery lesion or a common carotid artery lesion below the level of the clavicle or a postradiation treatment stenosis. Each procedure was categorized as high risk or low risk on the basis of presence of at least one of these criteria. Each patient could be classified in more than one high-risk category. Primary end points included death, stroke, or cardiac complications as defined by the reporting standards of an ad hoc committee of the Society of Vascular Surgery and the North American Chapter of the International Society for Cardiovascular JOURNAL OF VASCULAR SURGERY Volume 35, Number 1
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Surgery on cerebrovascular reporting. 13 Strokes were defined as the presence of a clinical neurologic deficit beyond 24 hours. Cardiac complications were defined as cardiac enzyme evidence of myocardial necrosis, an exacerbation of congestive heart failure that required additional hospitalization, or the new onset of atrial fibrillation. Transient ischemic attack, neurologic deficit lasting less than 24 hours, medically controlled angina, and cranial nerve injuries were not stratified as end points.
The specifics of the surgical procedure were left to the discretion of the operating surgeon, but the principles of the operative technique can be summarized in the following manner: the type of anesthesia was selected on the basis of the preferences of the surgeons and patients. Angiography was undertaken selectively when more anatomic information was required to define the indications for revascularization and the best operative technique. Selective shunting was used on the basis of neurologic changes with regional anesthesia, on the basis of electroencephalographic changes with general anesthetic, or when judged clinically appropriate by the operating surgeon. Synthetic patches were almost always used, with the rare exception determined by the operating surgeon. Completion studies were not routinely undertaken in the operating room and were reserved for abnormal anatomy or inadequate sounds with continuous wave Doppler scanning. The patients were typically monitored in the recovery room for 2 hours before transfer to a regular nursing unit specializing in vascular care. The intensive care unit was not routinely used.
The relationships between factors that potentially affected perioperative complications (stroke, cardiac morbidity, or death) were described with the calculation of the percent of patients with such events. Because the number of adverse events was small, assumptions underlying the traditional χ 2 test were not met. Therefore, statistical significance of differences between strata defined by the predictive factors was assessed with maximum likelihood ratio tests provided through logistic regression modeling. Logistic regression was also used to estimate the odds ratio for postoperative events associated with a 10-year difference in age (the only factor measured on a continuous scale). A P value of less than .05 was considered significant.
RESULTS
The patient characteristics are outlined in Table I . The population was predominately white male, with a mean age of 67 years (range, 41 to 92 years). Diagnostic contrast arteriography was undertaken before 238 procedures (54.9%) according to the discretion of the operating surgeon and the quality of noninvasive, preoperative imaging results.
Strokes. Seven procedures were complicated with postoperative ipsilateral strokes, and two additional procedures were complicated with contralateral hemispheric strokes that occurred from 7 to 19 days after the original CEA. One of these contralateral strokes occurred after a mitral valve replacement was undertaken for severe asymptomatic stenosis after the CEA. The second contralateral stroke occurred 19 days after a right CEA for 90% stenosis in a patient with bilateral visual disturbances. The patient underwent an uneventful left CEA for the 70% stenotic lesion 6 weeks after the stroke and had only minor hand numbness 30 days after the second operation. In addition, one patient died 9 days after the second CEA. Both of the CEAs required additional hospitalization for exacerbation of congestive heart failure. However, the patient died a sudden death at home after congestive heart failure had compensated. The total stroke and death rate was 2.4% after all procedures and 2.6% for all patients.
Seven other patients (two in the high-risk group and five in the low-risk group) had postoperative ipsilateral strokes that ranged from 0 to 9 days after the surgical procedures. Two major strokes (0.5%) occurred immediately after surgery, one related to middle cerebral artery embolization and the other to a low-flow state infarction in a patient with multisite intracranial disease despite the use of a shunt during the CEA. Five minor strokes (1.2%) occurred after surgery, including two that were related to reperfusion syndrome and two that were presumably related to minor embolization that could not be identified on radiographic study. The last minor stroke occurred 9 days after the original CEA when angiography was undertaken for the characterization of a false-positive defect found on a magnetic resonance image. Twelve patients (2.9%) were identified with cranial nerve deficits after the procedure, 11 of which involved the marginal mandibular nerve. All of the patients, except the one with a hypoglossal nerve injury, recovered completely within 30 days.
High-risk procedures. Ninety-eight of the 415 CEAs (23.6%) were classified as high-risk procedures. Specifically, contralateral occlusion, cardiac dysfunction, and recurrent carotid stenosis were the most common classifications for high-risk procedures (Table II) . Only 14 patients underwent carotid and either cardiac or aortic procedures within 30 days. Of the 14 patients who had more than one risk factor, none had strokes or cardiac morbidity. Forty of these 98 procedures (40.8%) were undertaken for symptomatic stenosis (nine for stroke, 27 for transient ischemic attack [TIA] , and four for amaurosis fugax), which was similar to the entire population of 415 procedures (Table I) .
Stroke rates in patients at high risk. In an evaluation of all of the high-risk procedures (n = 98), 4.1% of the patients had either stroke or death as compared with 1.9% of the patients in the low-risk group. None of the six risk factors could be identified as a significant predictor for stroke or death after CEA (Table III) . However, in a consideration of cardiac morbidity in addition to stroke or death, the patients at high risk had a total stroke, death, or cardiac outcome rate of 7.1% versus a 2.8% rate in the lowrisk group (P = .07). This cardiac morbidity rate difference was most dramatically seen in the cardiac dysfunction risk group (10.0% versus 0.8%; P = .004). Of note, only one patient in the high-risk cardiac group died and only three other patients had cardiac morbidity develop (two patients had MIs and one had an exacerbation of congestive heart failure). There was no significant difference in stroke rate between those patients who had contralateral carotid occlusion or recurrent carotid stenosis. No patients with recurrent carotid stenosis had a postoperative stroke, death, or cardiac complication.
Additional risk factors. Further risk factor analysis results provided additional information regarding stroke and cardiac morbidity rates (Table IV) . Female patients had both a higher stroke rate and a higher combined morbidity of stroke, death, or cardiac complication rate. Patients who were asymptomatic had a lower stroke rate (1.3%) as compared with patients who were symptomatic (3.9%; P = .09). In addition, the presence of coronary artery disease was associated with higher cardiac morbidity rate but did not adversely impact stroke rate. Furthermore, patients with diabetes had a higher stroke rate (5.6%) when compared with patients without diabetes (1.3%; P = .008). Also, a nearly equal number of procedures were accomplished with general anesthesia versus regional anesthesia. The stroke rate for general anesthesia procedures (2.3%) was similar to the rate of procedures accomplished with regional anesthesia (2.5%). However, the cardiac morbidity rate was 1% in the regional group and 1.9% in the general anesthesia group (P = .45). Age did not have a significant impact on stroke or cardiac morbidity.
DISCUSSION
After a period of careful scrutiny during the last 40 years, CEA has been shown to be a durable and effective treatment for symptomatic and asymptomatic carotid stenosis. Although most of the studies that established the efficacy of this procedure have been undertaken in a carefully selected population, the general medical consensus has applied the lessons learned from these studies to the general population. Subsequently, we and many clinicians around the country use CEA for a wide variety of patients. The advocates of carotid stenting have suggested that endarterectomy should not be so liberally applied outside the patient at normal risk. Furthermore, because there have been advancements in technologic capabilities in the area of carotid angioplasty, these same advocates have promoted the use of stenting for patients excluded from the JOURNAL OF VASCULAR SURGERY Volume 35, Number 1
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North American Symptomatic Carotid Endarterectomy Trial or Asymptomatic Carotid Atherosclerosis Study trials. However, although the procedural complications may have improved, the indications for carotid stenting and its efficacy remain undefined. In addition, there have been new developments in carotid stenting, such as lower profile systems, stents specifically designed for the carotid artery, and embolic protection devices. If these advancements do eventually improve the results and relative risk of carotid stenting, greater use for the procedure may be identified.
Our previous experience at the University of Alabama at Birmingham has identified a higher stroke rate in the carotid stenting group when compared with our endarterectomy experience. 7, 8 Subsequently, we have sought to determine an appropriate subgroup in which to apply this technique. Ouriel et al 11 identified certain physiologic factors (cardiac, renal, pulmonary dysfunction) that were associated with a higher stroke and non-stroke morbidity rate. In another report, Rothwell, Slattery, and Warlow 12 identified anatomic risk factors (contralateral occlusion, carotid siphon stenosis, external carotid stenosis) that also impacted stroke rate. We believe that the anatomic characteristics of the lesion (its location in the neck and the nature of the surrounding tissue) can affect the surgical morbidity rate more so than the physiologic factors of the patient (cardiac dysfunction, etc). At present, we recommend carotid stenting primarily for those lesions that are surgically inaccessible rather than for patients with poor physiologic risk factors. Yet "surgically inaccessible" can be a relative term. We balance the physiologic risk with the anatomic complexity for the determination of the surgical accessibility and then the best treatment method. For example, the stenting of a proximal common carotid lesion may be preferable to a sternotomy and arch reconstruction in some patients. In our opinion, clinicians should proceed cautiously when using carotid stenting solely because of physiologic risk factors.
We found in this analysis of our 415 procedures that the physiologic risks were not associated with a higher stroke risk but may have been associated with a slightly higher cardiac risk. Specifically, 47 procedures were classified as high risk because of the physiologic reasons of cardiac dysfunction, combined revascularization, or pulmonary dysfunction. The stroke rate was similar between these high (4.3%) and low (2.2%) physiologic risk groups, but the cardiac morbidity rate alone remains higher (6.4%) than the rate in the low physiologic risk group (0.8%). Carotid stenting, which might decrease cardiac morbidity rates in patients at high risk, would need to maintain similarly low stroke rates of CEA to be clinically effective for this group. In addition, these patients at high risk can undergo a surgical procedure with regional anesthesia with no effect on stroke risk rate (2.3% versus 2.5%; Table IV) and no difference in cardiac risk rate (1.9% versus 1.0%; Table IV) . We have previously reported that CEA with regional anesthesia has a stroke risk rate as low as 0.9%. 8 Subgroup analysis results in this series show a slightly higher rate (2.5%), but we still believe that CEA can be accomplished with regional anesthesia in those patients who may seem to be at a high risk for general anesthesia. Furthermore, although this study was not specifically designed for the evaluation of the effects of anesthetic technique, the results suggest that cardiac morbidity rates may not be affected by the type of anesthesia but instead by the patient's inherent coronary artery disease.
In a comparison of our results with the results of other reports, our combined stroke, death, and cardiac end point rates are not as contrasting in the patients at high risk as the results of some other reports. 9 This difference may represent a smaller sample size in our series (n = 415) as compared with the 3000 procedures reported by the Cleveland Clinic. However, our investigation analyzed the most recent 3 years, which may make it more applicable to today's population. In addition, our stroke rates compared favorably in both the high-risk and low-risk groups and fell within the guidelines of the American Heart Association's suggestion of stroke rate of less than 3% for asymptomatic and of less than 6% for symptomatic carotid occlusive disease. 14 A recent report that compared carotid angioplasty with CEA declared a similarity between these two therapies. 15 However, in the Carotid and Vertebral Artery Transluminal Angioplasty Study series, surgical stroke and death rates exceeded the stroke rate in this report (10.0% versus 2.6%). Specifically, 75% of these four deaths in the surgical arm of the CAVATAS report were related to nonneurologic causes, and the single death in our series was related to a cardiac cause (the patient died 9 days after a second CEA that was complicated with an exacerbation of congestive heart failure). With the consideration of the sample sizes (253 surgical CAVATAS patients to 415 patients in this series), our lower death rate may be related to a broader application of regional anesthesia (48% in this series versus 7% in CAVATAS) in patients who had a high physiologic risk. The cardiac morbidity rate was not significantly different in a comparison of anesthetic types, but our series was not randomized. Therefore, we cannot conclusively state that regional anesthesia has an impact on cardiac morbidity rates, although we tended to use regional anesthesia for the patient at high physiologic risk.
The primary weakness of carotid stenting may be the embolization that occurs in the inflation of a balloon and in the passing of devices through a diseased carotid bifurcation. Microemboli have been shown to occur at a substantially higher rate with carotid angioplasty when compared with surgery, 16 but because technologic advances have occurred, various methods of embolic protection associated with this procedure are becoming available. When the embolic load is reduced, the stroke risk may also be reduced. 17 Therefore, the availability of embolic protection may broaden the application of stenting. Currently, embolic reduction is under investigation in carotid stenting trials with a distal embolic capturing device for patients at high risk.
Finally, although carotid stenting is undergoing continued clinical trials and the Healthcare Finance Administration has limited reimbursement to only those protocols that are undergoing clinical trials, 18 we continue to pursue carotid stenting for anatomically inaccessible lesions. Specifically, we believe that the experienced carotid surgeon can make a better judgment about the technical aspects of carotid reconstruction as compared with an angiographer alone. Although the medical condition of the patient is an important consideration for any surgical therapy, the physiologic stress of CEA is quite low with a total stroke, death, and cardiac complication rate of 3.9%. Continued evaluation of carotid stenting should be undertaken in a carefully controlled clinical setting in which multiple disciplines should consider both the anatomic and physiologic risks of the patient.
This retrospective analysis has some limitations. Specifically, there was not an independent neurologist for the examination of all the patients. However, we found little difficulty in the identification of a neurologic deficit after a carotid procedure. The differentiation was more challenging in the consideration of the duration of the disability and, therefore, the classification of a TIA. Three patients had TIAs but had no persistent neurologic deficit beyond 24 hours and no radiographic evidence of stroke. An independent neurologist evaluated all of these patients with TIAs. In addition, the study size may have limited our ability to determine a real difference in these subgroups. Instead, 3200 patients would be required for the determination of a definite statistical difference between 2% and 4% in low-risk and high-risk groups. From a different perspective, a sample size of 400 would be needed for the definition of a difference of 10% stroke, death, or cardiac event rate in the high-risk group to have 80% probability of a difference in these two groups. Thus, our sample size and relatively low morbidity rates in both groups make the possibility of a real difference in stroke rates small. For a significant difference in future comparisons of CEA and carotid stenting, a large sample size will be required to avoid an apparent non-difference between the two therapies. However, smaller sample sizes can be sufficient if dramatic differences in the treatment methods are present. 5 
CONCLUSION
CEA can be undertaken in patients at high risk with acceptable stroke rates that are similar to the rates of patients at low risk. In a consideration of cardiac complications of MI, congestive heart failure, and atrial fibrillation along with all strokes and death, the total morbidity rate may be increased in the high-risk group. The current clinical application for carotid stenting should be limited to anatomically difficult lesions as determined by an experienced carotid surgeon. Otherwise, we maintain that the evaluation of carotid stenting should be done in carefully controlled clinical trials until further clinical evidence avails itself.
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Dr Kenneth Ouriel (Cleveland, Ohio). It's my pleasure to discuss this work of Dr Jordan's and his group, work that was directed at identifying a subset of carotid endarterectomy patients that are at higher than usual risk for complications.
As vascular surgeons, we know carotid endarterectomy to be one of our safest procedures. The rate of perioperative complications is lower than almost any peripheral vascular procedure, and the long-term durability of endarterectomy is extraordinary.
Herein lies the challenge for carotid stenting. To compete successfully against endarterectomy, stenting will need to be nearly equivalent with regard to stroke and death. Given the insecurities associated with this newer modality, we, as well as the UAB group, identified a high-risk subpopulation for whom stenting might be appropriate. This subgroup comprised just under one fourth of the UAB patients. Although the stroke rate was similar in the high-and low-risk groups, there were trends toward a higher rate of perioperative complications in the high-risk subset.
I have just two questions for the authors. First, given the relatively small sample size of this study, what is their feeling about the risk of a true difference in stroke or death being missed due to low power and a high probability of a Type II error?
And second, what is their view on performing any procedure, be it endarterectomy or stent, in a population with multiple medical comorbidities? Carotid endarterectomy has been shown to be of benefit in a relatively low-risk population with a considerable life expectancy. Are the prospects for long-term survival poor enough in this high-risk group that patients will not live long enough to pay off the debt of periprocedural complications? Dr William D. Jordan, Jr. I think you're absolutely correct in that one can examine the power that we have in the study. It was only 400 cases. And compared to the 3000 that were reported from Cleveland Clinic, our series is small.
We actually asked our statistician to evaluate that problem. He found that if there is a difference of 2% to 4%, which is roughly what we had, our sample size would need to be 3200 patients. That's going to take us a few more years in Birmingham to get that total.
We also looked at it from another perspective: what would the difference need to be with this small subset of patients? With only 400 patients, the difference would need to be 2% versus 10% in one group or the other.
I call your attention specifically to the Wallstent trial, because that randomized trial did have a difference, it was actually 4% versus 12% in that group. That trial was interrupted before its completion after a futility analysis. This trial abstract was presented in February 2001.
Your next point about those patients who have a limited life expectancy. We tend to be less aggressive for the asymptomatic patient who has a limited life expectancy. Specifically, we want to see at least 2 years before we operate on the asymptomatic patient. I think that when you truly find those who are symptomatic, we get a lot more aggressive. We tend to be less aggressive for the asymptomatic patient, and I think many patients are then treated medically.
Dr Peter R. F. Bell (Leicester, United Kingdom). Could I ask you one question?
There have now been three randomized trials: Our own in Leicester; the one you just quoted, with a 12.1% complication rate; and the CAVATAS trial which recently reported in Lancet 2 weeks ago with a 10% stroke rate following stenting. You said at the end of your last slide that we should do randomized studies. I have a problem with that. And the problem I have is how do you get informed consent from the patient when your stroke rate and death rate is 2%, as ours is? How do I tell a patient we should do a trial? Could you explain that to me, please? Dr Jordan. That issue is very important. My enthusiasm for randomization is still very quieted until the embolization problem is improved.
I'm specifically looking for embolic protection, via various means. I'm aware of the CAVATAS data and some report the stroke rate at 6%, but other reports have said 10%. At this point, because we still are seeking distal protection, I use carotid stenting for those who have surgically inaccessible lesions. As distal protection becomes more available and those data become available, I will then have more enthusiasm for enrolling patients in trials.
Dr Hero Van Urk (Rotterdam, The Netherlands). Since cardiac complications are a large proportion of your postoperative morbidity, I wonder whether you used beta blockers in your patients with a high cardiac risk, since we have shown that the use of beta blockers results in a tenfold decrease of postoperative cardiac morbidity.
And the second question is, did you use stress echocardiography or any other procedure like that to stratify your cardiac risk patients? Dr Jordan. We did not do stress testing for patients in terms of a cardiac evaluation. We usually would not undertake cardiac evaluation unless they had a suspicious clinical history, because we feel that the physiologic risks of a carotid procedure are quite low.
Your next question regarding beta blockade, we did not routinely use beta blockade. Since your publication, we've become more liberal with the use of beta blockers but did not specifically apply their use to this entire group.
Dr Geun Eun B. Kim (Seoul, South Korea). I'd like to know whether in your criteria for high-risk patients for stenting, did you consider plaque characteristic, such as B-mode finding of echolucent plaque? As we have reported previously, patients with the echolucent plaque are more symptomatic, and these patients may be more prone to embolization during the stenting.
Dr Jordan. No, we did not specifically separate our results based upon the duplex findings.
DISCUSSION

